Prelude Therapeutics posts investor presentation for SVB Global Biopharma Conference

Prelude Therapeutics Inc

Filed investor presentation under Regulation FD for Feb 2023 SVB conference.
Presentation attached as Exhibit 99.1 with no specific financial or clinical details in filing body.
No new material events, guidance changes, or operational updates disclosed in the 8-K text.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.